Macrolide-Resistant Mycoplasma genitalium Impairs Clinical Improvement of Male Urethritis After Empirical Treatment

Joyce F. Braam, MSc,* Alje P. van Dam, MD, PhD,**† Sylvia M. Bruisten, MD, PhD,*† Martijn S. van Rooijen, MSc, PhD,* Henry J.C. de Vries, MD, PhD,*‡ Maarten F. Schim van der Loeff, MD, PhD,*§ and Clarissa E. Vergunst, MD, PhD*¶

Background: Mycoplasma genitalium (MG) is associated with urethritis in men and could play a role in clinical outcome. We examined clinical improvement of symptoms in men receiving empirical treatment for urethritis and correlated the outcome with Neisseria gonorrhoeae (NG), Chlamydia trachomatis (CT), MG, and MG macrolide-resistant-associated mutations (MRAM) status.

Methods: At the sexually transmitted infection clinic in Amsterdam, the Netherlands, empirical treatment for gonococcal urethritis is 1 g ceftriaxone and for nongonococcal urethritis 1 g ceftriaxone and 500 mg azithromycin. We included all consecutive patients with urogenital symptoms at the STI clinic in Amsterdam who presented between January 1, 2014, and December 31, 2018, and underwent testing for NGU. From single-dose azithromycin to a course of doxycycline in their recent study, MG macrolide resistance had a prevalence of 74% (327 of 439). For 642 (25.6%) cases, we could evaluate clinical improvement after treatment of whom 127 (20%) indicated no improvement; 9% (15 of 174) in NG cases, 6% (10 of 168) in CT cases, and 2% (3 of 136) in MG cases. Clinical improvement in MG-MRAM cases was significantly lower compared with all other groups (P < 0.001).

Conclusions: Presence of MG-MRAM is associated with lack of clinical improvement in azithromycin-treated nongonococcal urethritis.

Acute urethritis in men is mostly caused by sexually transmitted infection (STI) Neisseria gonorrhoeae (CT) or Neisseria gonorrhoeae (NG).1 Distinction between gonococcal urethritis and nongonococcal urethritis (NGU) can be readily made by examination of Gram stains of discharge.2 Empirical treatment is often preferred over delay of treatment awaiting definite molecular test results. Empirical treatment in cases of gonococcal urethritis is ceftriaxone with or without azithromycin.3–5

In most clinical guidelines, identifying a pathogen in NGU is based on molecular testing.3,4,6,7 Recommendations on what pathogens to test vary somewhat, depending on local prevalence. All guidelines recommend testing for CT. The association of Mycoplasma genitalium (MG) with NGU was first described in the 1980s,8 and in the last 2 decades only after molecular tests became available, its role has become more apparent.1,9 Some guidelines, such as the Australian,6 have rapidly incorporated testing for MG. In contrast to Australian6 and European guidelines,7 the Centers for Disease Control and Prevention6 and Dutch4 guidelines currently do not recommend standard screening for MG in urethritis, but only in persisting or recurrent NGU.

Different treatment recommendations exist also for treatment of NGU, in part as a consequence of different testing guidelines for MG. Dutch guidelines9 still recommend the macrolide azithromycin (1 g single dose), whereas Australian6 and European guidelines recommend doxycycline (100 mg twice daily for 7 days). The Centers for Disease Control and Prevention changed its recommendation from single-dose azithromycin to a course of doxycycline in their recently updated guidelines.3 According to the Australian guidelines, patients with MG urethritis should be additionally treated with azithromycin (1 g stat then 500 mg daily for 3 days) or moxifloxacin (400 mg daily 7 days) after doxycycline resulting in a 10- to 14-day treatment course.6 The European guidelines recommend treatment with azithromycin (500 mg stat, then 250 mg for 4 days) in case of MG urethritis instead of treatment with doxycycline.7

According to a recent study performed at the STI clinics in Amsterdam and The Hague in 2018, the prevalence of MG among men with urogenital symptoms at the STI clinic in Amsterdam is 29%, whereas it was only 6% in 2014.12,13 Among the MG-positive samples in the recent study,MG macrolide resistance-associated mutations (MRAM) was detected in 66%.13 A review showed that there is a correlation between MG infection and persistent or recurrent NGU.14 Read et al.15 observed that

From the *Department of Infectious Diseases, Public Health Service of Amsterdam; †Department of Medical Microbiology, Amsterdam Institute for Infection and Immunity (All), ‡Department of Dermatology, and ¶Department of Internal Medicine, Amsterdam University Medical Center (UMC), Amsterdam; and †Department of Dermatology, NWZ, Den Helder, the Netherlands.

Acknowledgments: The authors would like to thank Mariska Hoogeland and Akke Cornelissen of the Public Health Service of Amsterdam for assistance with performing the molecular tests.

Funding was provided by the Public Health Laboratory of the Public Health Service (GGD) Amsterdam, the Netherlands. Hologic Inc, San Diego, CA, provided part of the diagnostic tests to detect Mycoplasma genitalium. Hologic had no role in study design, data collection, and analysis; decision to publish; or preparation of the manuscript.

Conflict of Interest and Sources of Funding: None declared.

Author Contributions: J.F.B.: investigation; formal analysis; writing – original draft; A.P.v.D., S.M.B., H.J.C.d.V., C.E.V.: conceptualization; writing – review and editing; M.S.v.R.: conceptualization; data curation; review and editing; M.F.S.v.d.L.: conceptualization; formal analysis; writing – review and editing.

Correspondence: Joyce F. Braam, MSc, Public Health Service of Amsterdam; GGD Amsterdam, Amsterdam, Noord-Holland, the Netherlands. E-mail: jbraam@ggd.amsterdam.nl.

Received for publication July 26, 2021, and accepted December 5, 2021. Supplemental digital content is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal’s Web site (http://www.stdjournal.com).

DOI: 10.1097/OLQ.0000000000001591

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Sexually Transmitted Diseases Association. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Treatment failure was thus associated with MG-MRAM. This—in combination with the high prevalence of MG and rapid increase of antibiotic resistance16—may indicate that current Dutch treatment guidelines for NGU need to be updated and take MG presence and MRAM into account. This study was designed to evaluate the clinical outcome of empirical treatment for both gonococcal urethritis and NGU and whether MG infection and MRAM are of influence.

METHODS

Setting of the Clinic
The study was performed at the STI clinic in Amsterdam, the Netherlands. The clinic is part of the Public Health Service, which means it is free of charge for members of the public at risk for STI, with or without referral. Diagnostics and treatment, including empirical treatment, are done according to Dutch guidelines.4 Testing in cases of male urethritis according to those guidelines includes CT and NG, but not MG. Testing for MG is currently only considered optional in cases of (persisting) urethritis. We performed this study to assess if testing for MG would benefit our patient population.

Cases Included
From May 2018 to November 2019, we included all men with urethritis at the STI outpatient clinic in Amsterdam. Men received standard care and treatment and could be included for different episodes. Urethritis was defined as presence of >10 leukocytes per high-power field in Gram stains of urethral discharge. Symptoms were dysuria, discharge, or urethral discomfort. Additional presence of intracellular gram-negative diplococci defined a presumptive diagnosis of gonococcal urethritis.

Treatment
Empirical treatment for gonococcal urethritis was 1 g ceftriaxone given intramuscularly and for NGU 1 g azithromycin per os, according to local and national guidelines.4 Testing in cases of male urethritis according to those guidelines includes CT and NG, but not MG. Testing for MG is currently only considered optional in cases of (persisting) urethritis. We performed this study to assess if testing for MG would benefit our patient population.

Molecular Detection of STIs
First-void urine was collected and routinely tested for NG and CT (Aptaera Combo 2; Hologic Inc, San Diego, CA). Samples with equivocal results were retested using the Aptaera CT single assay (Hologic Inc) and for NG with a quantitative polymerase chain reaction targeting opx genes.15 Urine samples were tested for MG using transcription- mediated amplification (TMA) assays (Aptaera, Hologic Inc). From all samples that tested positive for MG in the MG-TMA assay, DNA was extracted with isopropanol precipitation (Hologic Inc). From all samples that tested positive for MG in the MG-TMA assay, DNA was extracted with isopropanol precipitation and subsequently tested for macrolide resistance using the MG-MRAM quantitative polymerase chain reaction to detect wild-type (MG-WT) or any mutations (MRAM) in the 23S rRNA gene at nucleotide positions 2058 and 2059 (Escherichia coli numbering).18 Mycoplasma genitalium and MRAM testing were done for study purposes only, and results were disclosed neither to the men nor to the healthcare professionals. A subset of samples was tested for Trichomonas vaginalis (TV) using TMA assays (Aptaera, Hologic Inc).

Text Message
Men diagnosed with urethritis at initial consultation were informed about and asked to respond to an online survey sent to them by text message 2 weeks later. The text message was sent in Dutch and English. The question was, “How are the physical complaints that caused you to visit our clinic?” The answer options provided were as follows: “I did not have physical complaints,” “The physical complaints are gone,” “I’m doing better,” “The same, not improved,” and “I’m doing worse.”

Statistical Analysis
Only men with an initial consultation for urethritis were included in the analysis. Sociodemographic data, sexual behavior, the presence of clinical symptoms, recent antibiotic treatment, and antibiotics prescribed for the current case were extracted from electronic patient files. The variable “Education” was categorized into low (no education, primary school, lower secondary vocational education and intermediate secondary general education), mid (higher secondary general education, senior secondary vocational education, and preuniversity secondary education), and high (higher professional or university education). In the analysis, the answers “The physical complaints are gone” and “I’m doing better” were combined into one category, “improvement”; the answers “The same, not improved” and “I’m doing worse” were combined into one category, “no improvement.” We performed an additional analysis with a more stricter definition of clinical improvement: (1) the physical complaints are gone and (2) still having physical complaints (combining the other 3 answers in one category). The following men with urethritis were considered evaluable for clinical improvement analysis: men who indicated to have symptoms at the time of the consultation; who were tested for NG, CT, and MG; who were informed about the text message; who responded within 28 days after treatment; and of whom text message data were recorded. Treatments that were considered in analysis were treatments given up to 2 days before the completion of the online questionnaire regarding clinical improvement; several patients have received additional treatment after that time point. Univariable logistic regression analysis using generalized estimating equation was performed to compare the characteristics and infections of evaluable and nonevaluable cases and to compare cases indicating improvement to those reporting no improvement. Factors associated with clinical improvement were examined using generalized estimating equation logistic regression analysis. Variables included a priori in multivariable analysis were NG, CT, MG genotype, and age; variables with P < 0.20 in univariable analysis were considered in multivariable analysis, but only retained if P < 0.05. Significance was assessed 2-sided for all variables, applying a cutoff value of P < 0.05. Data were analyzed using Stata Intercooled 15 (StataCorp LLC, College Station, TX).

Ethics Statement
Men of the STI outpatient clinic Amsterdam were informed of the “opt-out” system regarding research on remnants of patient material. All data were pseudonymized before analysis. The study protocol was evaluated by the Medical Ethics Committee of the Academic Medical Center in Amsterdam (W18.013#18.024) and deemed not to require a full review of the board; signed informed consent was not deemed to be required.

RESULTS

Characteristics and Infection Status of All Urethritis Cases
We registered 2505 cases of urethritis in 2095 men in the study period (Fig. 1 and Supplementary Table 1, http://links.lww.
Mean (SD) age was 31.2 (10.4) years. The majority of cases were men who have sex with men (53%), most were of Dutch origin (41%) and had a high education level (63%), and 12% of the cases were HIV positive. 

**Neisseria gonorrhoeae**, **CT**, and **MG** test results were available from 2288 urethritis cases. In 768 (34%) cases, none of the 3 microorganisms were detected (Table 1). **Neisseria gonorrhoeae**, **CT** and **MG** were detected, respectively, 26%, 29%, and 23% of urethritis cases. **Mycoplasma genitalium** MRAM genotyping was successful in 439 of 522 MG positives (84%). Macrolide resistance-associated mutation was detected in 74% (327 of 439) of the successful MG-MRAM genotyped cases. Single infections were detected in 18% for NG, 21% for CT, and 14% for MG. Dual infections occurred in 4% for each pathogen combination and a triple infection in 1% of the urethritis cases (Table 1).

**No Differences in Infection Rates Between Evaluable and Nonevaluable Cases**

In 642 (25.6%) cases, clinical improvement after empirical treatment could be evaluated (Fig. 1). Evaluable cases were older (mean age, 32.7 vs. 30.7 years; \( P < 0.001 \)), were more often men who have sex with men (\( P = 0.002 \)), were more often of Dutch origin (\( P = 0.042 \)), and reported less often to have had urethritis symptoms in the past 2 years (\( P = 0.037 \)) compared with nonevaluable cases (Supplementary Table 1, http://links.lww.com/OLQ/A781).

**TABLE 1. Infection Status (Single, Dual, or Triple) of Urethritis Cases, by Evaluation Status and Reported Improvement, STI Clinic in Amsterdam, May 2018 to November 2019**

| NG | CT | MG | Total, n (%) | Evaluate*, n (%) | No Improvement in Evaluable Cases†, n (%) |
|----|----|----|--------------|-----------------|----------------------------------------|
| −  | −  | −  | 768 (34)     | 208 (27)        | 48 (23)                                |
| +  | −  | −  | 417 (18)     | 120 (29)        | 8 (7)                                  |
| −  | +  | −  | 486 (21)     | 155 (32)        | 24 (15)                                |
| −  | −  | +  | 320 (14)     | 87 (27)         | 33 (38)                                |
| +  | +  | −  | 95 (4)       | 14 (15)         | 1 (7)                                  |
| +  | −  | +  | 93 (4)       | 32 (34)         | 3 (9)                                  |
| −  | +  | +  | 81 (4)       | 18 (22)         | 7 (39)                                 |
| +  | +  | +  | 28 (1)       | 8 (29)          | 3 (38)                                 |
| Total | | | 2288 | 642 (28) | 120 (27) |

* \( \chi^2 \) Test was used to determine overall significance between evaluable and nonevaluable cases, \( P = 0.028 \).

† \( \chi^2 \) Test was used to determine overall significance between cases reporting improvement and no improvement, \( P < 0.001 \).

CT indicates Chlamydia trachomatis; MG, Mycoplasma genitalium; NG, Neisseria gonorrhoeae; STI, sexually transmitted infection.
Reported Clinical Improvement of Urethritis After Empirical Treatment

One hundred twenty-seven of the 642 evaluable cases (20%) indicated that their symptoms had not improved (Table 2). Patients infected with MG-MRAM had an OR of 3.38 (95% CI, 1.92–5.92) for no improvement 2 weeks after therapy compared with cases with MG reported no clinical improvement (7%-9%; Table 1 and Supplementary Fig. 1, http://links.lww.com/OLQ/A782). We additionally analyzed improvement considering single, dual, and triple infections (Fig. 2). Few patients with single NG infection, or with dual infections of NG + CT or NG + MG reported no clinical improvement (7%-9%; Table 1 and Supplementary Fig. 1, http://links.lww.com/OLQ/A782). Patients infected with single MG, dual CT + MG, or triple NG + CT + MG infection most often reported no improvement of symptoms (37%-39%).

In a subanalysis on all cases with an MG infection, cases with MG-MRAM had an OR of 4.00 (95% CI, 1.27–12.58) for no improvement 2 weeks after therapy compared with cases with MG-WT. After adjusting for CT and NG coinfection, age, and text-message response delay (not immediately responding to the text message but on days 15–28; adjusted odds ratio [aOR], 3.58; 95% CI, 2.05–6.24). Treatments with ceftriaxone and azithromycin were considered in the multivariable model but were both not significant. In the analysis in which we used a more stricter definition of clinical improvement, similar results were found (Supplementary Table 2, http://links.lww.com/OLQ/A781), except for ethnicity and CT infections, but these factors did not have a major effect on the association between MG-MRAM and clinical improvement. We performed a separate analysis for all NGU cases in which patients with MG-MRAM had a similar OR of 3.44 (95% CI, 2.04–5.80) for no improvement compared with patients with NGU not infected by MG (Supplementary Table 3, http://links.lww.com/OLQ/A781).

Antibiotic Treatment and Clinical Improvement

The majority of patients received only antibiotic treatment during their initial consultation (575 of 642 [90%]). Patients who attended the clinic after empirical treatment did this with a median of 7 days (range, 2–14 days). Patients were asked to attend the clinic in case of additional diagnostic findings on specimens taken at entry visit. Fifty-five patients received additional treatment at readmittance: 18 patients received ceftriaxone, 10 patients received azithromycin, 26 patients received doxycycline, and 1 patient received benzathine benzylpenicillin. Treatments that were considered in analysis were treatments given up to 2 days before the completion of the online questionnaire regarding clinical improvement. From all evaluable cases with an NG monoinfection, 98 of 120 (82%) had been treated with ceftriaxone alone, and 7% (7 of 98) indicated that their symptoms had not improved (Table 3). From the evaluable cases with a CT monoinfection, 131 of 155 (85%) were treated with azithromycin alone, and 17% (22 of 131) indicated no improvement. Evaluable cases with an MG monoinfection were treated with azithromycin alone in 81 of 87 of the cases (93%), and 40% (32 of 81) indicated that their symptoms had not improved (Table 3). Cases that were infected with MG-MRAM (monoinfection and coinfection) and that were treated with azithromycin indicated no improvement in 46% (33 of 71), whereas cases infected with MG-WT who were treated with azithromycin indicated no improvement in 15% (4 of 26; P = 0.005).

DISCUSSION

We evaluated patient-reported clinical outcome of empirical treatment in men with gonococcal and nongonococcal acute urethritis. Overall, the majority of NGU cases indicated clinical improvement after a single-dose azithromycin. Nevertheless, half of NGU cases testing positive for MG-MRAM did not report clinical improvement. The use of a single-dose azithromycin might therefore be continued for NGU cases without MG-MRAM. In gonococcal urethritis, empirically treated with ceftriaxone only, presence of MG did not affect clinical outcome.

Patients with NGU received empirical treatment with a single dose of oral azithromycin, according to current Dutch guidelines. Known advantages of this treatment compared with longer treatment regimens are compliance and tolerability. We now show for the first time that the presence of MG-MRAM significantly influences clinical outcome of empirical treatment for NGU and that 40% of the cases with MG-MRAM have persisting symptoms. Previously, Bachmann et al. reported a similar trend with more often persistent symptoms after treatment (26%) in MG-MRAM infected men in the United States, but this was not statistically significantly different compared with men with MG-WT infection or MG-negative men. In their study, the proportions of men with no improvement for MG-WT and without MG infection (13% and 17%, respectively) were comparable to those in our study (14% and 16%, respectively). In contrast, a meta-analysis found that 83% (76 of 92; 95% CI, 73%-90%) of individuals with MG-MRAM failed treatment with azithromycin. In the meta-analysis, treatment failure was defined as a positive test of cure. It could well be that antimicrobial treatment failure and symptom persistence differ considerably in case of MG-MRAM infections.

Interestingly, 46% of NGU patients with a single MG-MRAM infection indicated that their symptoms had not improved after treatment with azithromycin. Although this is higher compared with MG-WT (15%), this still means that half of the patients infected with MG-MRAM reported clinical improvement. This might mean that mutations do not cause full resistance to azithromycin, but that bacteria become less sensitive. Another explanation for clinical improvement despite MRAM is the anti-inflammatory effect of macrolides, which may also account for a reduction of symptoms. Another option is that the human body is in itself able to eliminate the bacterium to a certain extent. Research showed that the majority of women (74%-93%) may clear MG infection within 12 months. It is to be expected that men can also spontaneously clear MG infection. Lastly, antibiotic treatment might have also been effective to other causative bacteria we did not test for, such as Mycoplasma penetrans and Haemophilus species.
| No. Cases Without Clinical Improvement as a Fraction of Evaluable Cases | $P$ | OR 95% CI | aOR* 95% CI | 95% CI |
|---|---|---|---|---|
| **Total** | 127/642 (20%) | | | |
| Age in years, n (%) | | | | |
| <25 | 43/176 (24%) | 0.065 | 1 | |
| 25–34 | 53/247 (21%) | 0.79 | 0.50–1.27 | |
| 35–44 | 19/109 (17%) | 0.72 | 0.39–1.32 | |
| ≥45 | 12/110 (11%) | 0.39 | 0.19–0.78 | |
| Age per 10 y, mean (SD) | Mean age of 33 (11) y in cases with clinical improvement vs. mean age of 30 (10) y in cases without clinical improvement | 0.012 | 0.77 | 0.63–0.93 | 0.83 | 0.66–1.05 |
| Sexual risk group, n (%) | | | | |
| MSW | 66/263 (25%) | 0.008 | 1 | |
| MSM | 61/379 (16%) | 0.58 | 0.39–0.87 | |
| Country of origin, n (%) | | | | |
| The Netherlands | 49/296 (17%) | <0.001 | 1 | 1 |
| Turkey, Morocco, North Africa | 5/48 (10%) | 0.60 | 0.22–1.60 | 0.51 | 0.19–1.36 |
| Suriname | 38/90 (42%) | 3.66 | 2.14–6.26 | 3.38 | 1.91–6.00 |
| Europe, outside the Netherlands | 12/86 (14%) | 0.86 | 0.43–1.71 | 0.73 | 0.36–1.47 |
| Other | 23/122 (19%) | 1.20 | 0.68–2.09 | 1.02 | 0.56–1.87 |
| Educational level†, n (%) | | | | |
| Low | 11/56 (20%) | 0.280 | 1 | |
| Medium | 39/152 (26%) | 1.20 | 0.57–2.50 | |
| High | 68/391 (17%) | 0.82 | 0.41–1.64 | |
| Urethritis symptoms past 2 y, n (%) | | | | |
| No | 87/446 (20%) | 0.893 | 1 | |
| Yes | 40/196 (20%) | 1.03 | 0.66–1.60 | |
| Antibiotic use previous, n (%) | | | | |
| None | 103/525 (20%) | 0.591 | 1 | |
| Last 7 d | 2/14 (14%) | 0.72 | 0.17–3.00 | |
| Last 14–21 d | 1/14 (7%) | 0.39 | 0.08–1.91 | |
| Last 30 d | 6/29 (21%) | 1.32 | 0.61–2.87 | |
| Last 90 d | 15/60 (25%) | 1.30 | 0.69–2.44 | |
| Text message response in days, n (%) | | | | |
| 14 | 68/395 (17%) | 0.048 | 1 | 1 |
| 15–28 | 59/247 (24%) | 1.48 | 1.00–2.18 | 1.60 | 1.04–2.44 |
| HIV, n (%) | | | | |
| Negative | 93/425 (22%) | 0.104 | 1 | |
| Positive | 11/94 (12%) | 0.47 | 0.23–0.95 | |
| Unknown | 23/123 (19%) | 0.84 | 0.51–1.38 | |
| No. sex partners in the last 6 mo‡, n (%) | | | | |
| 0 or 1 | 10/54 (19%) | 0.397 | 1 | |
| 2–4 | 56/241 (23%) | 1.33 | 0.66–2.69 | |
| 5–9 | 32/173 (18%) | 0.93 | 0.44–1.95 | |
| ≥10 | 29/172 (17%) | 0.90 | 0.43–1.92 | |
| Received azithromycin, n (%) | | | | |
| No | 22/192 (11%) | 0.001 | 1 | |
| Yes | 105/450 (23%) | 2.52 | 1.44–4.39 | |
| Received doxycycline, n (%) | | | | |
| No | 118/586 (20%) | 0.152 | 1 | |
| Yes | 9/56 (16%) | 0.55 | 0.25–1.24 | |
| Received ceftriaxone, n (%) | | | | |
| No | 110/467 (24%) | <0.001 | 1 | |
| Yes | 17/175 (10%) | 0.36 | 0.21–0.63 | |
| NG, n (%) | | | | |
| Negative | 112/468 (24%) | <0.001 | 1 | 1 |
| Positive | 15/174 (9%) | 0.32 | 0.18–0.56 | 0.28 | 0.15–0.52 |
| CT, n (%) | | | | |
| Negative | 92/447 (21%) | 0.517 | 1 | 1 |
| Positive | 35/195 (18%) | 0.87 | 0.56–1.33 | 0.67 | 0.40–1.11 |
| MG, n (%) | | | | |
| Negative | 81/497 (16%) | <0.001 | 1 | 1 |
| Positive | 46/145 (32%) | 2.20 | 1.41–3.45 | |

Continued next page
TABLE 2. (Continued)

| MG genotype, n (%) | No. Cases Without Clinical Improvement as a Fraction of Evaluable Cases | P    | OR   | 95% CI | aOR*  | 95% CI |
|--------------------|------------------------------------------------------------------------|------|------|--------|-------|--------|
| Negative for MG    | 81/497 (16%)                                                           | <0.001 | 1    | 1      |       |        |
| WT                 | 4/28 (14%)                                                             | 0.59 | 0.12–2.90 | 0.58  | 0.17–2.05 |
| MRAM               | 38/94 (40%)                                                            | 3.38 | 2.11–5.40 | 3.58  | 2.05–6.24 |
| Unknown            | 4/23 (17%)                                                             | 1.16 | 0.44–3.07 | 1.10  | 0.35–3.50 |

Univariable and multivariable logistic regression with GEE was used to determine risk factors for no improvement.

*aOR indicates adjusted odds ratio; GEE, generalized estimating equation; MG, *Mycoplasma genitalium*; MRAM, macrolide resistance-associated mutations; MSM, men who have sex with men; MSW, men who have sex with women only; NG, *Neisseria gonorrhoeae*; OR, odds ratio; STI, sexually transmitted infection; WT, wild-type.

We also looked into the treatment success of patients with gonococcal urethritis, in combination with coinfections with CT and MG. Few cases infected with NG + MG reported no improvement (9%), in spite of the fact that, in most of these cases, treatment consisted of ceftriaxone only, whereas ceftriaxone is unlikely to affect MG directly. This suggests that MG infection in urethritis is of less clinical importance in the presence of NG. Although asymptomatic MG infections are common, it is striking that, in this symptomatic patient group, clinical treatment failure was so limited, considering the amount of MG coinfections found in the gonococcal urethritis cases in this study (19% [121 of 633]).

In 34% of urethritis cases in our study, no NG, CT, or MG was detected. This finding is consistent with data from other urethritis studies. Although an array of other possible pathogens such as TV, herpes simplex virus, and adenovirus, *Haemophilus influenzae* and *M. penetrans* are associated with urethritis, a large proportion of NGU cases remain without microbial etiology. Another consistent finding throughout urethritis research is the suboptimal clinical response to antimicrobial treatment. Whether or not these findings are related, their consistency is remarkable and suggests that we should consider other, nonmicrobial causes for urethral inflammation.

We found a surprisingly high proportion of men of Surinamese origin who reported no clinical improvement, and Surinamese ethnicity was independently associated with no clinical improvement. Surinamese men had NG infections relatively less often, but they had more MG infections and also more coinfections (Supplementary Table 4, http://links.lww.com/OLQ/A781). Moreover, the proportion of MG-MRAM was relatively high. However, these differences were not statistically significant compared with other ethnicities. We hypothesized that this might be due to infection with TV, which is relatively common among people of Surinamese origin. In the Netherlands, prevalence of TV is relatively low (between 0.4% and 0.5%) and therefore not routinely tested for. In the study from van der Veer et al., half of the patients with a TV infection were of Surinamese or Dutch Antillean origin. In a subset of 55 of 90 Surinamese men, we found that only one man was infected with TV, so this cannot explain the large proportion of Surinamese men reporting no clinical improvement. Another explanation might be ethnic differences in the immune response. Previously, it was shown that there is a difference in immune responses between European and African populations. Dutch men are predominantly of European descent, whereas many Surinamese men have a more mixed, including African and Southeast Asian, background. Further research is needed to understand why Surinamese men report clinical improvement less often.

Only 35% (705 of 2000) of the men who were eligible responded to the text message, which raises the question whether results might have been biased because men with persisting symptoms may have been more likely to respond than men without. Although the response rates to our text message was much lower than expected, we decided to extend the study instead of intensifying requests for response, which would have certainly induced

![Figure 2](image-url). Reported improvement of evaluable cases, by infection status (single, dual, or triple), STI clinic in Amsterdam, May 2018 to November 2019. Percentages above the bars indicate the proportion of evaluable cases without improvement. Overall $\chi^2$ test, $P < 0.001$. STI, sexually transmitted infection; NG, *Neisseria gonorrhoeae*; CT, *Chlamydia trachomatis*; MG, *Mycoplasma genitalium*.
TABLE 3. Treatment Given and Reported Improvement of Evaluable Urethritis Cases, by Infection Status (None, Single, Dual, or Triple), STI Clinic in Amsterdam, May 2018 to November 2019

| Infections | No NG, CT or MG, n (%) | NG Only, n (%) | NG + CT, n (%) | NG + MG, n (%) | CT + MG, n (%) | NG + CT + MG, n (%) | Total, n (%) |
|------------|------------------------|----------------|---------------|---------------|---------------|---------------------|-------------|
|            | 48/208 (23)            | 8/120 (7)      | 24/155 (15)   | 33/87 (38)    | 1/14 (7)      | 3/32 (9)            | 127/642 (20) |

*Treatments listed here are treatments given up to 2 days before the completion of the online questionnaire regarding clinical improvement; several patients have received additional treatment after that time point.

Number of cases without clinical improvement are given as a fraction of evaluable cases.

CT indicates Chlamydia trachomatis; MG, Mycoplasma genitalium; STI, sexually transmitted infection.

bias. We think the chance of a bias due to the low response rate is low, because there were no differences in infection rates between evaluable and nonevaluable cases (Table 1 and Supplementary Table 1, http://links.lww.com/OLQ/A781). We included a large number of cases and used a silent study design without additional study visits and treatment interventions. To our knowledge, this is the only study analyzing the effect of MG and MG-MRAM on clinical improvement after empirical treatment with this design. Because of this real-life design, we were unable to evaluate urine or discharge for microbiological cure or signs of persistent urethritis. However, we believe that symptoms experienced after treatment by a patient are as important and valid as microbiological cure in the evaluation of treatment efficacy. A recent study from Australia showed that even with extended courses of resistance-guided therapy, 100% microbiological cure could not be achieved.27

To conclude, although a majority of NGU cases reported clinical improvement after empirical treatment with a single-dose azithromycin, the improvement was significantly lower in NGU cases with MG-MRAM. Presence of MG did not hamper clinical improvement in gonococcal urethritis treated with a single-dose ceftriaxone. Therefore, we recommend testing for and treating MG-MRAM especially in patients with NGU. Resistance-guided treatment might be considered as treatment approach for NGU.27

REFERENCES

1. Moi H, Blee K, Horner PJ. Management of non-gonococcal urethritis. BMC Infect Dis 2015; 15:294.
2. Bartoletti R, Wagenlehner FME, Bjerkland Johansen TE, et al. Management of urethritis: Is it still the time for empirical antibiotic treatments? Eur Urol Focus 2019; 5:29–35.
3. Centers for Disease Control and Prevention. Sexually Transmitted Disease Treatment Guidelines 2021. Available at: https://www.cdc.gov/std/treatment-guidelines/toc.htm. Updated July 22, 2021. Accessed November 20, 2020.
4. Netherlands Association of Dermatology and Venereology. Multidisciplinary guideline on diagnostics and treatment of sexually transmitted infections 2018 (update 2019) [in Dutch]. Available at: https://www.soaaids.nl/files/2019-07/multidisciplinair-richtlijn-soa-2018-update-2019.pdf. Accessed October 18, 2019.
5. Unemo M, Ross J, Servin AB, et al. 2020 European guideline for the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS 2020; 956462420949126.
6. Australasian Sexual Health Alliance. Australian STI Management Guidelines, Urethritis—Male 2018. Available at: http://www.sti.guidelines.org.au/syndromes/urethritis-male. Updated October 4, 2018. Accessed July 21, 2021.
7. Horner PJ, Blee K, Falk L, et al. 2016 European guideline on the management of non-gonococcal urethritis. Int J STD AIDS 2016; 27:928–937.
8. Tully JG, Taylor-Robinson D, Cole RM, et al. A newly discovered mycoplasma in the human urogenital tract. Lancet 1981; 1:1288–1291.
9. Horner PJ, Martin DH. Mycoplasma genitalium infection in men. J Infect Dis 2017; 216(suppl 2):S396–S405.
10. Shahmanesh M, Moi H, Lassau F, et al., IUSTI/WHO. 2009 European guideline on the management of male non-gonococcal urethritis. Int J STD AIDS 2009; 20:458–464.
11. Workowski KA, Berman S, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59(RR-12):1–110.
12. van der Veer C, van Rooijen MS, Himschoot M, et al. Chlamydia trachomatis vaginalis and Mycoplasma genitalium: Age-specific prevalence and disease burden in men attending a sexually transmitted infections clinic in Amsterdam, the Netherlands. Sex Transm Infect 2016; 92:83–85.
13. Hetem DJ, Kuizenga Wessel S, Bruisten SM, et al. High prevalence and resistance rates of Mycoplasma genitalium among patients visiting two sexually transmitted infection clinics in the Netherlands. Int J STD AIDS 2021; 32:837–844.
14. Taylor-Robinson D, Jensen JS. Mycoplasma genitalium: From chrysalis to multicolored butterfly. Clin Microbiol Rev 2011; 24:498–514.
15. Read TR, Fairley CK, Tabrizi SN, et al. Azithromycin 1.5g over 5 days compared to 1g single dose in urethral *Mycoplasma genitalium*: Impact on treatment outcome and resistance. Clin Infect Dis 2017; 64:250–256.

16. Machalek DA, Tao Y, Shilling H, et al. Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in *Mycoplasma genitalium*: A systematic review and meta-analysis. Lancet Infect Dis 2020; 20:1302–1314.

17. Geraats-Peters CW, Brouwers M, Schneeberger PM, et al. Specific and sensitive detection of *Neisseria gonorrhoeae* in clinical specimens by real-time PCR. J Clin Microbiol 2005; 43:5653–5659.

18. Braam JF, Hetem DJ, Vergunst CE, et al. Evaluating the prevalence and risk factors for macrolide resistance in *Mycoplasma genitalium* using a newly developed qPCR assay. PLoS One 2020; 15:e0240836.

19. Peters DH, Friedel HA, McTavish D. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 1992; 44:750–799.

20. Bachmann LH, Kirkcaldy RD, Geisler WM, et al. Prevalence of *Mycoplasma genitalium* infection, antimicrobial resistance mutations, and symptom resolution following treatment of urethritis. Clin Infect Dis 2020; 71:e1684–e1693.

21. Horner P, Ingle SM, Garrett F, et al. Which azithromycin regimen should be used for treating *Mycoplasma genitalium*? A meta-analysis. Sex Transm Infect 2018; 94:14–20.

22. Martínez FJ, Curtis JL, Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008; 3:331–350.

23. Vandepitte J, Weiss HA, Kyakuwa N, et al. Natural history of *Mycoplasma genitalium* infection in a cohort of female sex workers in Kampala, Uganda. Sex Transm Dis 2013; 40:422–427.

24. Oakeshott P, Aghaizu A, Hay P, et al. Is *Mycoplasma genitalium* in women the “new chlamydia”? A community-based prospective cohort study. Clin Infect Dis 2010; 51:1160–1166.

25. Sarier M, Kukul E. Classification of non-gonococcal urethritis: A review. Int Urol Nephrol 2019; 51:901–907.

26. Srinivasan S, Chambers LC, Tapia KA, et al. Urethral microbiota in men: Association of *Haemophilus influenzae* and *Mycoplasma penetrans* with nongonococcal urethritis. Clin Infect Dis 2020; 71:1461–1468.

27. Read TR, Fairley CK, Murray GL, et al. Outcomes of resistance-guided sequential treatment of *Mycoplasma genitalium* infections: A prospective evaluation. Clin Infect Dis 2019; 68:554–560.

28. Nijhuis RHT, Duinsbergen RG, Pol A, et al. Prevalence of *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, *Mycoplasma genitalium* and *Trichomonas vaginalis* including relevant resistance-associated mutations in a single center in the Netherlands. Eur J Clin Microbiol Infect Dis 2021; 40:591–595.

29. Nedelec Y, Sanz J, Baharian G, et al. Genetic ancestry and natural selection drive population differences in immune responses to pathogens. Cell 2016; 167:657–669.e21.